Abstract: Objective To explore the efficacy and safety of nucleos(t)ide analogs (NAs) in treatment of patients with chronic hepatitis B(CHB).Methods 94 outpatients with CHB from December 2012 to February 2013 were recruited to the open observational study. The adefovir dipivoxil (ADV) group, lamivudine (LAM) group and entecavir (ETV) group included 30 patients, 28 patients and 36 patients respectively. All included patients continuously took ADV, LAM or ETV for 96 weeks. We observed and compared the aminotransferase (ALT) normalization rate, virological response rate, HBeAg seroconversion rate, and adverse drug event (ADE) incidence.Results At 4th week and 8th week, ALT of three groups had been significantly improved, but there were no statistical differences（P﹥0.05）. At 12th week and 24th week, there were significant differences in virological response rate (P﹤0.05), among which the ADV group was significantly lower than the ETV group（P﹤0.017）. At 48th week and 96th week, there were no statistical differences（P﹥0.05）in virological response rate. There were no significant differences in HBeAg seroconversion rate among three groups（P﹥0.05）.Conclusion NAs are suitable for long-term use for the treatment of CHB patients with high safety, of which ETV should be as an initial choice.

Key words: chronic hepatitis B, nucleos(t)ide analog, biochemical response rate, virological response rate, HBeAg seroconversion rate